Compare IPHA & EPM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IPHA | EPM |
|---|---|---|
| Founded | 1999 | 2003 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.3M | 137.2M |
| IPO Year | 2014 | 1996 |
| Metric | IPHA | EPM |
|---|---|---|
| Price | $2.01 | $3.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $5.75 | $4.83 |
| AVG Volume (30 Days) | 52.7K | ★ 625.6K |
| Earning Date | 03-26-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 10.08% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,229,621.00 |
| Revenue This Year | $180.36 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.18 | $3.19 |
| 52 Week High | $2.71 | $5.70 |
| Indicator | IPHA | EPM |
|---|---|---|
| Relative Strength Index (RSI) | 43.42 | 51.85 |
| Support Level | $1.67 | $3.48 |
| Resistance Level | $1.95 | $3.74 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 0.00 | 79.01 |
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.